Engineered immune cells take on metastatic tumors in new trial

NCT ID NCT03412877

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 5 times

Summary

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exhausted standard treatments. The approach involves collecting immune cells, engineering them, and infusing them back along with supportive drugs to boost their activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genetically engineered white blood cells (T-cells)
What this could lead to: If successful, this could offer a new treatment option for patients with advanced cancers that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply to everyone. The treatment involves strong chemotherapy and can cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm colorectal cancer digestive system cancer endocrine gland neoplasm malignant endocrine neoplasm malignant urinary system neoplasm neuroendocrine neoplasm non-small cell lung carcinoma ovarian cancer plasma cell myeloma Urogenital Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER ENDOCRINE TUMORS GASTROINTESTINAL/GENITOURINARY CANCERS MULTIPLE MYELOMA NEUROENDOCRINE TUMORS NON-SMALL CELL LUNG CANCER OVARIAN CANCER

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.